{
  "source": "PA-Med-Nec-Adynovate.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2024 P 2110-9\nProgram Prior Authorization/Medical Necessity\nMedication Adynovate® (antihemophilic factor [recombinant], pegylated)\nP&T Approval Date 10/2016, 10/2017, 10/2018, 10/2019, 9/2020, 9/2021, 9/2022, 9/2023,\n9/2024\nEffective Date 12/1/2024\n1. Background:\nAdynovate (antihemophilic factor [recombinant], pegylated) is a recombinant antihemophilic\nfactor indicated in adults and children with hemophilia A (congenital Factor VIII deficiency)\nfor:1\nOn-demand treatment and control of bleeding episodes\no\nRoutine prophylaxis to reduce the frequency of bleeding episodes\no\nPerioperative management\no\nAdynovate is not indicated for the treatment of von Willebrand disease.\n2. Coverage Criteriaa:\nA. Initial Authorization\n1. Adynovate will be approved based on all of the following criteria:1-3\na. Diagnosis of hemophilia A\n-AND-\nb. Patient is not a suitable candidate for treatment with shorter acting half-life Factor VIII\n(recombinant) products [Advate, Kogenate FS, Kovaltry, Novoeight, Nuwiq, or\nRecombinate] as attested by the prescriber\n-AND-\nc. One of the following:\n(1) Both of the following:\n(a) Patient is not to receive routine infusions more frequently than 2 times per week\n-AND-\n(b) Patient is not to receive a routine dose greater than 50 IU/kg\n© 2024 UnitedHealthcare Services, Inc.\n1\n-OR-\n(2) All of the following\n(a) Patient is less than 12 years of age\n-AND-\n(b) Patient is not to receive routine infusions more frequently than 2 times per week\n-AND-\n(c) Patient is not to receive a routine dose greater than 70 IU/kg\nAuthorization of therapy will be issued for 12 months\nB. Reauthorization\n1. Adynovate will be approved based on both of the following criteria:\na. Documentation of positive clinical response to Adynovate therapy\n-AND-\nb. One of the following:\n(1) Both of the following:\n(a) Patient is not to receive routine infusions more frequently than 2 times per\nweek\n-AND-\n(b) Patient is not to receive ",
    "o Adynovate therapy\n-AND-\nb. One of the following:\n(1) Both of the following:\n(a) Patient is not to receive routine infusions more frequently than 2 times per\nweek\n-AND-\n(b) Patient is not to receive a routine dose greater than 50 IU/kg\n-OR-\n(2) All of the following\n(a) Patient is less than 12 years of age\n-AND-\n(b) Patient is not to receive routine infusions more frequently than 2 times per\nweek\n-AND-\n(c) Patient is not to receive a routine dose greater than 70 IU/kg\n© 2024 UnitedHealthcare Services, Inc.\n2\nAuthorization of therapy will be issued for 12 months\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply\n3. Additional Clinical Programs:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-10)\nand/or claim logic. Use of automated approval and re-approval processes varies by program\nand/or therapeutic class.\n4. References:\n1. Adynovate® [package insert]. Lexington, MA: Baxalta US, Inc., August 2023.\n2. Hoots WK, Shapiro AD. Hemophilia A and B: Routine management including prophylaxis.\nIn: UpToDate, Waltham, MA, 2024.\n3. Recommendations Concerning Products Licensed for the Treatment of Hemophilia and\nSelected Disorders of the Coagulation System. MASAC Document #284, April 11, 2024.\nProgram Prior Authorization/Medical Necessity - Adynovate\nChange Control\n10/2016 New program.\n10/2017 Updated background and criteria to note updated indication. Revised\nformatting without changes to clinical intent outside of new indication.\nUpdated state mandate verbiage. Updated references.\n10/2018 Annual review with no changes to coverage criteria. Updated\nreference.\n10/2019 Annual review with no changes to coverage criteria. Updated\nreference.\n9/2020 Modified criteria aligning with coverage criteria for other cover",
    "changes to coverage criteria. Updated\nreference.\n10/2019 Annual review with no changes to coverage criteria. Updated\nreference.\n9/2020 Modified criteria aligning with coverage criteria for other covered\nextended half-life recombinant factors. Removed exclusion notation\nsince addition to coverage. Updated references.\n9/2021 Annual review with no changes to coverage criteria. Updated\nreference.\n9/2022 Annual review with no changes to coverage criteria. Updated\nreferences.\n9/2023 Annual review. Modified physician attestation to prescriber attestation.\nUpdated references.\n9/2024 Annual review with no changes to coverage criteria. Updated\nreferences.\n© 2024 UnitedHealthcare Services, Inc.\n3"
  ]
}